The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Recombinant pharmaceuticals from microbial cells: a 2015 update
Open accessAbstract
Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
A comprehensive review of genetic association studies
Hirschhorn, J. N., Lohmueller, K., Byrne, E., & Hirschhorn, K. (2002) · Genetics in Medicine · doi:10.1097/00125817-200203000-00002 · Cited by 1,674
Production of recombinant proteins by microbes and higher organisms
Demain, A. L., & Vaishnav, P. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.01.008 · Cited by 1,028
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Lammers, T., Aime, S., Hennink, W. E., Storm, G., & Kiessling, F. (2011) · Accounts of Chemical Research · doi:10.1021/ar200019c · Cited by 870
Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias
Weatherall, D. J. (2001) · Nature Reviews Genetics · doi:10.1038/35066048 · Cited by 692
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy
Lohcharoenkal, W., Wang, L., Chen, Y. C., & Rojanasakul, Y. (2014) · BioMed Research International · doi:10.1155/2014/180549 · Cited by 655
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Microbial factories for recombinant pharmaceuticals
Ferrer-Miralles, N., Domingo-Espín, J., Corchero, J. L., Vázquez, E., & Villaverde, A. (2009) · Microbial Cell Factories · doi:10.1186/1475-2859-8-17 · Cited by 465
Self-citation
Cited by
E. coli strain engineering for the production of advanced biopharmaceutical products
Selas Castiñeiras, T., Williams, S. G., Hitchcock, A. G., & Smith, D. C. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny162 · Cited by 92
Green biologics: the algal chloroplast as a platform for making biopharmaceuticals
Taunt, H. N., Stoffels, L., & Purton, S. (2018) · Bioengineered · doi:10.1080/21655979.2017.1377867 · Cited by 81
Current advances in the algae-made biopharmaceuticals field
Rosales-Mendoza, S., Solís-Andrade, K. I., Márquez-Escobar, V. A., González-Ortega, O., & Bañuelos-Hernandez, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1739643 · Cited by 55
Rourou, S., Ben Zakkour, M., & Kallel, H. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.05.092 · Cited by 53
Heterologous production of cyanobacterial compounds
Dhakal, D., Chen, M., Luesch, H., & Ding, Y. (2021) · Journal of Industrial Microbiology and Biotechnology · doi:10.1093/jimb/kuab003 · Cited by 33
“, 2018), due to its easy and flexible culturing, fast growth, cost-effectiveness, andwell-established genetic manipulation tools (Kaur et al., 2018; Sanchez-Garcia et al., 2016).”
Background
Metadata
- Authors
- Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A.
- Venue
- Microbial Cell Factories
- Published
- 2016-02-09
- Volume
- 15
- Issue
- 1
- Pages
- 33-33
- ISSN
- 1475-2859 (ISSN-L)
- OpenAlex
- W2253053879
- Cited by
- 339
- References
- 38
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant pharmaceuticals from microbial cells: a 2015 update. https://app.cochat.ai/papers/10.1186/s12934-016-0437-3
- The paper
- Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial Cell Factories. https://doi.org/10.1186/s12934-016-0437-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
